中国首款口服GLP-1减肥药获批

新浪财经
Nov 12

  11月12日晚间消息,今日,礼来中国宣布其穆优达(奥氟格列隆钙片,以下简称“奥氟格列隆”)获得国家药品监督管理局批准为1类新药上市。这是国内首个获批用于成人体重管理的口服GLP-1受体激动剂。 

  该药物适用于在控制饮食和增加运动基础上,用于肥胖或超重并伴有至少一种体重相关合并症的成人体重管理。其成人2型糖尿病适应症正在国家药监局审批过程中。

  此前,我国获批的GLP-1类减重药均需皮下注射。而奥氟格列隆是一款小分子、非肽类GLP-1受体激动剂,只需每日口服一次,不受进食和饮水限制。

  今年4月,奥氟格列隆在美国获批,用于成人减重。这是全球首个获批上市的口服小分子非肽类GLP-1受体激动剂。据礼来最新财报显示,该产品自第二季度上市以来,累计贡献了2.81亿美元的收入,第三季度收入为1.84亿美元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10